This company has been acquired
Applied Genetic Technologies Future Growth
Future criteria checks 2/6
Key information
6.5%
Earnings growth rate
29.5%
EPS growth rate
Biotechs earnings growth | 23.6% |
Revenue growth rate | 68.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Recent updates
AGTC receives positive feedback from FDA for manufacturing facility
Jul 26Applied Genetic Technologies proposes stock offering to fund clinical trials
Jul 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022
Jan 12An Assessment Of Applied Genetic Technologies Corporation
Dec 14Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Jul 15Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?
May 21What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?
Feb 05Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?
Jan 06What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 11Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2025 | 12 | -100 | -127 | -99 | 2 |
6/30/2024 | N/A | -90 | -110 | -93 | 3 |
6/30/2023 | 0 | -78 | -96 | -87 | 5 |
9/30/2022 | 0 | -70 | -68 | -66 | N/A |
6/30/2022 | 0 | -69 | -68 | -66 | N/A |
3/31/2022 | 1 | -63 | -63 | -61 | N/A |
12/31/2021 | 1 | -63 | -60 | -58 | N/A |
9/30/2021 | 1 | -60 | -56 | -54 | N/A |
6/30/2021 | 1 | -58 | -53 | -51 | N/A |
3/31/2021 | N/A | -60 | -53 | -52 | N/A |
12/31/2020 | N/A | -57 | -50 | -49 | N/A |
9/30/2020 | 2 | -50 | -45 | -44 | N/A |
6/30/2020 | 2 | -46 | -43 | -42 | N/A |
3/31/2020 | 3 | -42 | -37 | -35 | N/A |
12/31/2019 | 24 | -19 | -34 | -34 | N/A |
9/30/2019 | 28 | -15 | -35 | -35 | N/A |
6/30/2019 | 42 | -2 | -24 | -23 | N/A |
3/31/2019 | 47 | 2 | -23 | -23 | N/A |
12/31/2018 | 29 | -18 | -24 | -23 | N/A |
9/30/2018 | 28 | -19 | -24 | -23 | N/A |
6/30/2018 | 24 | -21 | -33 | -33 | N/A |
3/31/2018 | 27 | -18 | -37 | -36 | N/A |
12/31/2017 | 32 | -11 | -37 | -37 | N/A |
9/30/2017 | 38 | -4 | -35 | -34 | N/A |
6/30/2017 | 39 | 0 | -32 | -31 | N/A |
3/31/2017 | 43 | 6 | -29 | -28 | N/A |
12/31/2016 | 47 | 10 | -31 | -28 | N/A |
9/30/2016 | 48 | 11 | -32 | -30 | N/A |
6/30/2016 | 47 | -1 | N/A | 71 | N/A |
3/31/2016 | 36 | -12 | N/A | 72 | N/A |
12/31/2015 | 24 | -20 | N/A | 75 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGTC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AGTC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AGTC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AGTC's revenue (68% per year) is forecast to grow faster than the US market (7% per year).
High Growth Revenue: AGTC's revenue (68% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGTC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/12/01 16:07 |
End of Day Share Price | 2022/11/30 00:00 |
Earnings | 2022/09/30 |
Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Applied Genetic Technologies Corporation is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
James Birchenough | BMO Capital Markets Equity Research |
Yun Zhong | BTIG |
Kristen Kluska | Cantor Fitzgerald & Co. |